SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in HNC

(InSilico Medicine, Inc.) The researchers identified that SMAD4 loss results in cetuximab resistance in vitro and poor survival in HPV-negative HNSCC patients and in vivo models. Using OncoFinder (an innovative bioinformatic tool currently rebranded as iPANDA), they revealed a signature of pro-survival and anti-apoptotic pathways specifically dysregulated in SMAD4-low HNSCCs and indicate JNK and MAPK activation as potential mediators of cetuximab resistance.

Source: EurekAlert! - Medicine and Health - July 7, 2017 Category: International Medicine & Public Health Source Type: news